<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03973281</url>
  </required_header>
  <id_info>
    <org_study_id>MaternaMedical</org_study_id>
    <nct_id>NCT03973281</nct_id>
  </id_info>
  <brief_title>EASE: The Materna Prep Pivotal Study</brief_title>
  <official_title>A Randomized, Controlled Study to Evaluate the Safety and Effectiveness of the Materna Prep Device to Pre-stretch (i.e., Dilate) the Vaginal Canal and Pelvic Floor Tissues in Preparation for Vaginal Delivery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Materna Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Baylor College of Medicine - Texas Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Materna Medical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the safety and effectiveness of the Materna Prep Device in&#xD;
      reducing pelvic muscle injuries during vaginal delivery.&#xD;
&#xD;
      Subjects are randomized to Materna Prep Device or Standard of Care without use of the Materna&#xD;
      Prep Device&#xD;
&#xD;
      Intervention with the Materna Prep Device is expected to be a one-time use of approximately&#xD;
      30-90 minutes during the 1st stage of labor.&#xD;
&#xD;
      Subject participation in the study is targeted to be 3 months from the time of the use of the&#xD;
      device during delivery. Subjects who elect to continue participation in the long term follow&#xD;
      up portion of the study will extend their time in the study to 10 years.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary effectiveness endpoint: Reduction in the rate of pelvic muscle injury defined as&#xD;
      complete or partial detachment of the levator ani muscle diagnosed via ultrasound imaging at&#xD;
      3-month follow-up.&#xD;
&#xD;
      Primary safety endpoint: Data on maternal and neonatal adverse events will be gathered and&#xD;
      evaluated. Adverse events will be further summarized by relatedness to the device and/or&#xD;
      procedure, seriousness, and level of severity.&#xD;
&#xD;
      Secondary endpoints&#xD;
&#xD;
        -  Reduction in the length of second stage of labor, defined as the time from when the&#xD;
           cervix is dilated to 10cm to the complete delivery of the baby.&#xD;
&#xD;
        -  Reduction in Levator Hiatus Area (measurement between pelvic muscle and pelvic bone)&#xD;
           determined at 3-month ultrasound follow-up.&#xD;
&#xD;
        -  Reduction in the rate of perineal lacerations determined by visual inspection&#xD;
           post-delivery.&#xD;
&#xD;
        -  Reduction in the rate of instrument use in vaginal deliveries.&#xD;
&#xD;
        -  Reduction in the rate of OASI&#xD;
&#xD;
        -  Rate of C-Sections due to cephalopelvic disproportion.&#xD;
&#xD;
        -  Infant APGAR scores.&#xD;
&#xD;
        -  Qualitative pain and pelvic health feedback.&#xD;
&#xD;
        -  User satisfaction&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 11, 2019</start_date>
  <completion_date type="Anticipated">June 22, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 22, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized Control Study</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>The physician reading all ultrasound images will be blinded to randomization</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in the rate of pelvic muscle injury defined as complete or partial detachment of the levator ani muscle</measure>
    <time_frame>3-month Follow-up</time_frame>
    <description>Use ultrasound to measure Levator Hiatus defect and Levator Urethral Gap between device and control groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction in the length of second stage of labor</measure>
    <time_frame>Intra-Procedure</time_frame>
    <description>Shorten the pushing time for delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in Levator Hiatus Area</measure>
    <time_frame>3-month Follow-up</time_frame>
    <description>Reduce the rate of perineal lacerations between device and control groups determined at 3-month ultrasound follow up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduce Perineal Lacerations</measure>
    <time_frame>Intra-Procedure</time_frame>
    <description>Reduce the rate of perineal lacerations between device and control groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in the rate of instrument use in vaginal deliveries</measure>
    <time_frame>Intra-Procedure</time_frame>
    <description>Reduce use of instrument during deliveries</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in the rate of OASI</measure>
    <time_frame>Intra-Procedure</time_frame>
    <description>Reduce the tearing of the muscles of the anal sphincter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of C-Sections due to cephalopevic disproportion</measure>
    <time_frame>Intra-Procedure</time_frame>
    <description>Reduce the rate of C-Sections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infant APGAR scores</measure>
    <time_frame>Intra-Procedure</time_frame>
    <description>Increase APGAR scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Qualitative pain and pelvic health feedback</measure>
    <time_frame>3-Month Follow-up</time_frame>
    <description>Reduce pain and pelvic injury</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>User Satifaction</measure>
    <time_frame>3-Month Follow-up</time_frame>
    <description>Obtain positive user satisfaction</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">283</enrollment>
  <condition>Childbirth</condition>
  <arm_group>
    <arm_group_label>Materna Prep Device</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Materna Prep Device</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care (SOC)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Standard of Care (SOC)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Materna Prep Device</intervention_name>
    <description>Materna Prep Device</description>
    <arm_group_label>Materna Prep Device</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of Care (SOC)</intervention_name>
    <description>Standard of Care (SCO)</description>
    <arm_group_label>Standard of Care (SOC)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Criteria for inclusion 1. Subject scheduled for vaginal birth. 2. Subject gestating a&#xD;
        single fetus. 3. Subject nulliparous, or had a previous pregnancy terminated within 24&#xD;
        weeks gestation. 4. Subject able and willing to comply with the protocol required follow-up&#xD;
        visits. 5. Subjects able and willing to provide written informed consent prior to&#xD;
        enrollment. 6. Subject has sufficient mental capacity to: understand the informed consent&#xD;
        form (ICF), comply with the protocol requirements, and provide clinically relevant and&#xD;
        reliable feedback regarding their experience with the device. 7. Subject receives epidural&#xD;
        anesthesia during labor prior to using the device. 8. Subject 18 years of age or older at&#xD;
        time of consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Criteria for exclusion 1. Subject has high likelihood of less than 1 hours of potential&#xD;
        device dilation time after she arrives at the hospital 2. Subject has need for or is&#xD;
        planning a Caesarean-section 3. Subject begins labor with less than 36 weeks gestation 4.&#xD;
        Subject has neurological diseases, e.g. Multiple Sclerosis, that may result in unrelated&#xD;
        pelvic disorders or has been diagnosed with HIV. 5. Subject has muscular or skin disorder&#xD;
        that affects elasticity of tissue, such as scleroderma or lupus.6. Subject has evidence of&#xD;
        local or systemic infection, or has active herpes infection. 7. Subject has any prior&#xD;
        surgical procedures to the vaginal anatomy which could lead to pelvic dysfunction, pelvic&#xD;
        fractures, or pelvic soft tissue injuries. 8. Subject has any general health condition or&#xD;
        systemic disease that may represent, in the opinion of the investigator, a potential&#xD;
        increased risk associated with device use or pregnancy. 9. Subject has placenta previa or&#xD;
        vasa previa 10. Known significant chromosomal or structural fetal anomalies 11. Category 2&#xD;
        and/or 3 fetal tracing that is unresolved&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hang Nguyen</last_name>
    <phone>866-433-6933</phone>
    <email>hang@maternamed.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jenny Lester</last_name>
      <email>JLester@mednet.ucla.edu</email>
    </contact>
    <contact_backup>
      <last_name>Ross Divinagracia</last_name>
      <email>Rossmar@mednet.ucla.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Tammy Grisales, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>El Camino Hospital</name>
      <address>
        <city>Mountain View</city>
        <state>California</state>
        <zip>94040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michell Backer</last_name>
      <email>Michelle_Backer@elcaminohealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Divya Patel, MA</last_name>
      <email>Divya@elcaminowomen.com</email>
    </contact_backup>
    <investigator>
      <last_name>Sarah Azad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amy Teng, DO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Erika Balassiano, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pooja Gupta, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kara M Rood, MD</last_name>
      <phone>404-321-0264</phone>
      <email>kara.rood@osumc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Taryn L Summerfield, MS</last_name>
      <phone>614-293-2122</phone>
      <email>taryn.summerfield@osumc.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francisco Orejuela, MD</last_name>
      <phone>832-826-7735</phone>
      <email>Francisco.Orejuela@bcm.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 31, 2019</study_first_submitted>
  <study_first_submitted_qc>May 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2019</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Shorten Delivery Time, Pelvic Muscle Injury, Vaginal Delivery, Complications, Childbirth, prevention</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>General demographic data and outcome measures will be made available to other researchers</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

